Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Springer

Showing results (121-130 of 121) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 121 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG Saturno, F Lopes, I Niculescu-Duvaz, et al.
Pageof 13

Showing results (121-130 of 121) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 121 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2020
The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancersG Saturno, F Lopes, I Niculescu-Duvaz, et al.
Pageof 13